CAPN2 Antibody

What is CAPN2 and what cellular functions does it regulate?

CAPN2 (Calpain-2) is a calcium-regulated non-lysosomal thiol-protease that catalyzes limited proteolysis of substrates involved in cytoskeletal remodeling and signal transduction . It is also known as CANPL2, m-calpain, CANPml, mCANP, or FLJ39928, belonging to the peptidase C2 family .

CAPN2 functions include:

• Proteolytic cleavage of substrates like MYOC at 'Arg-226'

• Proteolytic cleavage of CPEB3 following neuronal stimulation

• Regulation of matrix metalloproteinases (MMPs) such as MMP-2 and MMP-9

• Involvement in epithelial-mesenchymal transition (EMT) processes

• Participation in cell cycle regulation and mitotic processes

Unlike other proteases that completely degrade substrates, CAPN2 typically produces cleaved products that retain biological activity, often with modified functions compared to the intact protein .

What types of CAPN2 antibodies are available for research applications?

Several types of CAPN2 antibodies are available for research purposes:

When selecting an antibody, researchers should consider:

• The intended application (WB, IHC, IF, etc.)

• Species reactivity requirements

• Mono vs. polyclonal (monoclonals offer higher specificity but may recognize fewer epitopes)

• Validation data available for the specific application and tissue/cell type

What are the recommended protocols for optimizing CAPN2 immunohistochemistry staining?

For optimal CAPN2 immunohistochemistry staining, researchers should consider the following methodology:

Sample Preparation:

• For FFPE tissues, use 4-6μm thick sections mounted on positively charged slides

• The recommended antigen retrieval method varies by antibody:

  • TE buffer pH 9.0 is suggested for many CAPN2 antibodies

  • Alternative retrieval can be performed with citrate buffer pH 6.0

Staining Protocol:

• Deparaffinize sections and wash with 3% H₂O₂

• Perform antigen retrieval with appropriate buffer

• Block non-specific binding

• Incubate with primary anti-CAPN2 antibody at optimized dilution:

  • For monoclonal antibody 66977-1-Ig: 1:2000-1:8000

  • For polyclonal antibody 11472-1-AP: 1:50-1:500

• Apply secondary antibody and develop using DAB

• Counterstain with hematoxylin

Assessment Method:
For semiquantitative scoring:

• Score staining intensity: 0 (negative), 1 (weak), 2 (moderate), 3 (strong)

• Score percentage of positive cells: 0 (0%), 1 (<25%), 2 (25-50%), 3 (50-75%), 4 (>75%)

• Calculate final score by multiplying intensity and percentage scores

What controls should be included when working with CAPN2 antibodies?

Proper experimental controls are essential when working with CAPN2 antibodies:

Positive Controls:

• Validated cell lines with known CAPN2 expression:

  • A549 cells, HeLa cells, MDA-MB-231 cells show strong CAPN2 expression

  • For cancer research: PC-3, CAKI-1, 769-P (high expression)

• Tissue controls:

  • Human placenta tissue

  • Brain tissue (mouse/rat)

  • Pancreatic cancer tissue

Negative Controls:

• Primary antibody omission control (use PBS instead)

• CAPN2 knockdown or silencing using siRNA/shRNA

• Normal human pancreatic duct cell line (HTERT-HPNE) shows lower CAPN2 expression compared to pancreatic cancer cell lines

Specificity Controls:

• Blocking peptide assay

• Use multiple antibodies targeting different epitopes of CAPN2

• Western blot to confirm the observed molecular weight (72-80 kDa)

How can I troubleshoot weak or non-specific signals when using CAPN2 antibodies?

When encountering issues with CAPN2 antibody applications, consider these methodological solutions:

For Weak Signal:

• Optimize antibody concentration - titration is recommended for each system

• Extend primary antibody incubation time or temperature

• Enhance antigen retrieval:

  • Try alternative buffers (TE pH 9.0 vs. citrate pH 6.0)

  • Extend heat treatment time

• Use signal amplification systems (HRP polymers, tyramide amplification)

• Verify sample preparation and storage conditions

For High Background/Non-specific Signal:

• Increase blocking time/concentration

• Reduce primary antibody concentration

• Add additional washing steps

• Use monoclonal antibodies for higher specificity

• Ensure freshness of reagents, especially detection substrates

• For IHC, consider tissue-specific autofluorescence quenching

Application-Specific Troubleshooting:

• Western Blot: For premium antibodies like Picoband (M03492), expect superior quality, high affinity, and strong signals with minimal background

• IHC: Pre-absorption with antigen may reduce non-specific staining

• IF/ICC: Higher dilutions are often needed (e.g., 1:400-1:1600 for 66977-1-Ig)

How does CAPN2 expression correlate with cancer progression and patient outcomes?

CAPN2 expression has been extensively studied in multiple cancer types, with several studies demonstrating significant correlations with disease progression and clinical outcomes:

Renal Cell Carcinoma (RCC):

• CAPN2 is significantly overexpressed in RCC tissues compared to adjacent non-tumor tissues

• Strong CAPN2 staining correlates with higher clinical stage and histological grade

• Associated with enhanced migration, invasion, and proliferation of RCC cells

Pancreatic Cancer (PC):

Castration-Resistant Prostate Cancer (CRPC):

• CAPN2 mRNA is upregulated in CRPC cells (DU145 and PC3) compared to non-CRPC cells

• Silencing CAPN2 inhibits proliferation through G1 phase cell cycle arrest

• CAPN2 knockdown suppresses migration and invasion capabilities

This consistent pattern across multiple cancer types suggests CAPN2 may serve as a potential prognostic biomarker and therapeutic target in various malignancies.

What signaling pathways are regulated by CAPN2 in cancer progression?

CAPN2 exerts its oncogenic effects through multiple signaling pathways:

AKT/mTOR Signaling:

• In renal cell carcinoma, CAPN2 activates the AKT/mTOR signaling pathway

• CAPN2 knockdown reduces phosphorylation of AKT and mTOR proteins

• This pathway activation contributes to enhanced cell proliferation and survival

EMT Regulation:

• CAPN2 enhances epithelial-mesenchymal transition (EMT) in multiple cancer types

• In pancreatic cancer, CAPN2 regulates EMT through the Wnt/β-catenin pathway

• CAPN2 silencing decreases expression of EMT markers

MMP Regulation:

• CAPN2 positively regulates MMP-2 and MMP-9 expression and activation

• In prostate cancer, CAPN2 knockdown suppresses MMP-2 and MMP-9 activation

• This regulation affects extracellular matrix degradation, enabling invasion and metastasis

LIMK1/Cofilin-1 Pathway:

• In breast cancer cells, CAPN2 binds, cleaves, and activates LIM Kinase-1 (LIMK1)

• Activated LIMK1 phosphorylates cofilin-1 (CFL1)

• CAPN2 depletion leads to accumulation of full-length LIMK1 and inhibits CFL1/LIMK1 binding

• This pathway affects nuclear structure, chromosome movement, and mitosis

These findings highlight CAPN2's pleiotropic role in cancer progression through multiple signaling networks, making it a potential target for cancer therapeutics.

What is the specific role of CAPN2 in nuclear functions and mitotic processes?

Recent research has uncovered CAPN2's critical nuclear functions, particularly during mitosis:

Nuclear Localization:

• CAPN2 abundance determines its nucleolar localization during interphase

• CAPN2 interacts with nucleolar proteome components, including the actin-severing protein cofilin-1 (CFL1)

LIMK1 Regulation:

• CAPN2 binds, cleaves, and activates LIM Kinase-1 (LIMK1) in the nuclear compartment

• This cleavage represents a novel mechanism for LIMK1 activation

• CAPN2 depletion causes:

  • Increased full-length LIMK1 levels

  • Inhibited CFL1/LIMK1 binding

  • LIMK1 accumulation at cell periphery and perinucleolar region

Mitotic Functions:

• CAPN2 regulates mitosis-specific increase of CFL1 phosphorylation and localization

• CAPN2 depletion leads to:

  • Altered CFL1 phosphorylation patterns

  • Aberrant mitosis

  • Cell multinucleation

Nuclear Structure Maintenance:

• CAPN2 influences cytoskeleton remodeling essential for:

  • Maintenance of nuclear structure

  • Movement of chromosomes

  • Modulation of transcription

These findings suggest CAPN2's role extends beyond its canonical cytoplasmic functions, highlighting its importance in nuclear compartment organization and mitotic processes frequently altered in cancer cells.

How can researchers effectively design CAPN2 knockdown experiments?

Designing effective CAPN2 knockdown experiments requires careful methodological considerations:

siRNA/shRNA Design:

• Use multiple independent siRNA/shRNA sequences targeting different regions of CAPN2 mRNA

• Validate knockdown efficiency at both mRNA and protein levels

• Example from published research:

  • Two independent siRNAs (siCAPN2 #1 and siCAPN2 #2) used in pancreatic cancer studies

  • Western blotting used to confirm knockdown effects

Controls:

• Include appropriate non-targeting siRNA/shRNA controls

• Consider rescue experiments by reintroducing siRNA-resistant CAPN2 to confirm specificity

• Include positive controls (e.g., cells with known CAPN2 expression levels)

Functional Assays:
After CAPN2 knockdown, assess multiple cellular functions:

Timeline Considerations:

• Assess protein knockdown 48-72 hours post-transfection

• For migration/invasion assays, begin observations within 6-24 hours

• For proliferation, extend observations to 72 hours

These methodological approaches will ensure robust and reproducible CAPN2 knockdown experiments.

How do CAPN2 expression patterns differ across tissue types and what are the implications for antibody validation?

CAPN2 exhibits variable expression across tissue types, presenting unique challenges for antibody validation:

Tissue-Specific Expression Patterns:

Validation Requirements by Tissue Type:

• For high-expressing tissues/cells:

  • Validate antibody specificity using knockdown/knockout approaches

  • Use lower antibody concentrations (e.g., 1:5000-1:50000 for Western blot)

  • Verify specificity with multiple antibodies targeting different epitopes

• For low-expressing tissues/cells:

  • More sensitive detection methods may be required

  • Signal amplification techniques should be considered

  • Lower dilutions of antibody may be necessary

• Cancer vs. normal tissue comparison:

  • Include both tissue types as internal controls

  • Validate using paired tumor-normal samples when possible

  • Consider IHC on tissue microarrays containing multiple tissue types

Application-Specific Considerations:

• For Western blot: Expected molecular weight is 72-80 kDa

• For IHC: Different antigen retrieval methods may be required for different tissues

• For IF/ICC: Background signals vary by cell type, requiring optimization

Understanding these tissue-specific expression patterns is critical for proper experimental design and interpretation of results when using CAPN2 antibodies.